EUVIMEDEUVIMED entdecken
Open Access

Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies

Wei Shi iD, Yin Wang iD, Yuehui Zhao, Justin Jimin Kim, Haoyan Li iD, Chenling Meng, Feiyu Chen, Jie Zhang, Duncan H Mak, Vivien Van, Javier Leo, Brad St Croix iD und 2 weitere

Science Translational Medicine · 10.05.2023 · 15 (695)

DOI: 10.1126/scitranslmed.adf6724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 10.05.2023. Verfasst von Wei Shi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Checkpoint immunotherapy has yielded meaningful responses across many cancers but has shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7-H3/ CD276 ) is an immune checkpoint molecule and has emerged as a promising therapeutic target. However, much remains to be understood regarding B7-H3’s role in cancer progression, predictive biomarkers for B7-H3–targeted therapy, and combinatorial strategies. Our multi-omics analyses identified B7-H3 as one of the most abundant immune checkpoints in prostate tumors containing PTEN and TP53 genetic inactivation. Here, we sought in vivo genetic evidence for, and mechanistic understanding of, the role of B7-H3 in PTEN/TP53- deficient prostate cancer. We found that loss of PTEN and TP53 induced B7-H3 expression by activating transcriptional factor Sp1. Prostate-specific deletion of Cd276 resulted in delayed tumor progression and reversed the suppression of tumor-infiltrating T cells and NK cells in Pten/Trp53 genetically engineered mouse models. Furthermore, we tested the efficacy of the B7-H3 inhibitor in preclinical models of castration-resistant prostate cancer (CRPC). We demonstrated that enriched regulatory T cells and elevated programmed cell death ligand 1 (PD-L1) in myeloid cells hinder the therapeutic efficacy of B7-H3 inhibition in prostate tumors. Last, we showed that B7-H3 inhibition combined with blockade of PD-L1 or cytotoxic T lymphocyte–associated protein 4 (CTLA-4) achieved durable antitumor effects and had curative potential in a PTEN/TP53 -deficient CRPC model. Given that B7-H3–targeted therapies have been evaluated in early clinical trials, our studies provide insights into the potential of biomarker-driven combinatorial immunotherapy targeting B7-H3 in prostate cancer, among other malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMaleAnimalsMiceCell Line, TumorTumor Suppressor Protein p53Sp1 Transcription FactorUp-RegulationDisease ProgressionB7 AntigensPTEN PhosphohydrolaseCTLA-4 Antigen

Substanzen

Tumor Suppressor Protein p53Sp1 Transcription FactorCd276 protein, mouseB7 AntigensPten protein, mousePTEN PhosphohydrolaseCtla4 protein, mouseCTLA-4 Antigen

Autor:innen und Institutionen

  • Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Biology, Colby College, Waterville, ME 04901, USA.
  • Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.

ORCID-Profile: Wei Shi, Yin Wang, Haoyan Li, Brad St Croix, Ana Aparicio, Di Zhao

Förderung

  • NCI NIH HHS

Zitieren

APA

Shi, W., Wang, Y., Zhao, Y., Kim, J. J., Li, H., Meng, C., Chen, F., Zhang, J., Mak, D. H., Van, V., Leo, J., St Croix, B., Aparicio, A., & Zhao, D. (2023). Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Science Translational Medicine, 15(695). https://doi.org/10.1126/scitranslmed.adf6724

Vancouver

Shi W, Wang Y, Zhao Y, Kim JJ, Li H, Meng C, et al. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Science Translational Medicine. 2023;15(695). doi:10.1126/scitranslmed.adf6724

BibTeX
@article{Shi2023,
  author = {Shi, Wei and Wang, Yin and Zhao, Yuehui and Kim, Justin Jimin and Li, Haoyan and Meng, Chenling and Chen, Feiyu and Zhang, Jie and Mak, Duncan H and Van, Vivien and Leo, Javier and St Croix, Brad and Aparicio, Ana and Zhao, Di},
  title = {Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies},
  journal = {Science Translational Medicine},
  year = {2023},
  volume = {15},
  number = {695},
  doi = {10.1126/scitranslmed.adf6724}
}
Kostenlos starten →